10月20日，凯莱英盘中上涨3.2%，报142.0港元，成交额5418.06万港元。
消息面上，公司将于10月22日审议前三季度业绩；与此同时，公募三季报显示，南方港股医药行业混合曾大幅加仓凯莱英，并将其升至第一大重仓股，强化了市场对CXO及创新药链条的关注。
同日制药板块表现活跃，翰森制药上涨7.12%，礼邦医药-B上涨5.43%，恒瑞医药上涨4.2%，中国生物制药上涨3.24%，石药集团上涨3.1%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.